Table 2.
Effect of eugenol on gene expression profile of apoptotic Ca9-22.
| Expression profile of apoptotic Ca9-22 | ||||
|---|---|---|---|---|
| Unigene | Refseq | Symbol | Description | Fold change |
| Hs. 377484 | NM_004323 | BAG1 | BCL2-associated athanogene | 2.01 |
| Hs. 227817 | NM_004049 | BCL2A1 | BCL2-related protein A1 | 5.48 |
| Hs. 283672 | NM_020396 | BCL2L10 | BCL2-like 10 (apoptosis facilitator) | − 2.24 |
| Hs. 469658 | NM_006538 | BCL2L11 | BCL2-like 11 (apoptosis facilitator) | 4.36 |
| Hs. 410026 | NM_004050 | BCL2L2 | BCL2-like 2 | 3.04 |
| Hs. 517145 | NM_001196 | BID | BH3 interacting domain death agonist | − 2.72 |
| Hs. 131226 | NM_004331 | BNIP3L | BCL2/adenovirus E1B 19KDa interacting protein 3-like | 3.57 |
| Hs. 550061 | NM_004333 | BRAF | V-raf murine sarcoma viral oncogene homolog B1 | 5.87 |
| Hs. 2490 | NM_033292 | CASP1 | Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, converatse) | − 3.96 |
| Hs. 5353 | NM_001230 | CASP10 | Caspase 10, apoptosis-related cysteine peptidase | 2.06 |
| Hs. 466057 | NM_012114 | CASP 14 | Caspase 14, apoptosis-related cysteine peptidase | 2.26 |
| Hs. 213327 | NM_004347 | CASP 5 | Caspase 5, apoptosis related cysteine peptidase | 15.61 |
| Hs. 329502 | NM_001229 | CASP9 | Caspase 9, apoptosis related cysteine peptidase | 2.15 |
| Hs. 355307 | NM_001242 | CD27 | CD27 molecule | − 3.11 |
| Hs. 501497 | NM_001252 | CD70 | CD70 molecule | − 2.96 |
| Hs. 38533 | NM_003805 | CRADD | CASP2 and RIPK1 domain containing adaptor with death domain | − 4.98 |
| Hs. 380277 | NM_004938 | DAPK1 | Death-associated protein kinase 1 | 2.06 |
| Hs. 169611 | NM_019887 | DIABLO | Diablo, IAP-binding mitochondrial protein | 2.05 |
| Hs. 667309 | NM_000043 | FAS | Fas (TNF receptor superfamily, member 6) | 2.68 |
| Hs. 643120 | NM_000875 | IGF1R | Insulin-like growth factor 1 receptor | − 3.50 |
| Hs. 646951 | NM_004536 | NAIP | NLR family, apoptosis inhibitory protein | 2.03 |
| Hs. 618430 | NM_003998 | NFKB1 | Nuclear factor of Kappa light polypeptide gene enhancer in B-cells 1 | 2.56 |
| Hs. 499094 | NM_013258 | PYCARD | PYD and CARD domain containing | − 3.54 |
| Hs. 109755 | NM_003821 | RIPK2 | Receptor-interacting serine-threonine kinase 2 | 4.39 |
| Hs. 241570 | NM_000594 | TNF | Tumor necrosis factor | 2.76 |
| Hs. 661668 | NM_003842 | TNFRSF10B | Tumor necrosis factor receptor superfamily, member 10b | 2.47 |
| Hs. 256278 | NM_001066 | TNFRSF1B | Tumor necrosis factor receptor superfamily, member 1B | − 2.11 |
| Hs. 738942 | NM_001561 | TNFRSF9 | Tumor necrosis factor receptor superfamily, member 9 | 2.42 |
| Hs. 478275 | NM_003810 | TNFSF10 | Tumor necrosis factor (ligand) superfamily, member 10 | − 4.02 |
| Hs. 654445 | NM_001244 | TNFSF8 | Tumor necrosis factor (ligand) superfamily , member 8 | 2.14 |
| Hs. 460996 | NM_003789 | TRADD | TNFRSF1A-associated via death domain | − 2.09 |
QPCR array data corresponding to apoptotic genes expression profile. A total of 84 markers were analyzed following incubation with an intermediate concentration of eugenol estimated at 200 µM. The treatment duration was limited to 24 h. Unigene designator, Refseq identifier, symbol and description corresponding to all factors showing discrepancies relative to untreated control are summarized in Table 2. Only the genes displaying over two-fold variation were taken into consideration. This indicative study corresponds to only one experiment (n = 1).